# Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"

> **NCT03555578** · — · RECRUITING · sponsor: **Takeda** · enrollment: 1890 (estimated)

## Conditions studied

- Spinal and Bulbar Muscular Atrophy

## Interventions

- **DRUG:** Leuprorelin Acetate

## Key facts

- **NCT ID:** NCT03555578
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2017-11-02
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 1890 (ESTIMATED)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03555578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03555578, "Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03555578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*